Mariner’s Neurogene NGNE Stock Holding History

Mariner’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$386K	Sell	12,260 -4,427	-27%	-$122K	﹤0.01%	2637
2026 Q1	$336K	Buy	+16,687	New	+$323K	﹤0.01%	2765
2025 Q1	–	Sell	-10,475	Closed	-$239K	–	3542
2024 Q4	$239K	Buy	+10,475	New	+$390K	﹤0.01%	2842

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Mariner's NGNE Position: Q2 2026 in Review

Mariner reduced its Neurogene (NGNE) stake by 27% in Q2 2026, selling an estimated $122K and leaving 12,260 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

Mariner first reported a position in NGNE in Q4 2024 and has held it in 3 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

Mariner held 12,260 shares of Neurogene worth $386K as of Q2 2026.
Mariner sold 4,427 Neurogene shares in Q2 2026, an estimated $122K.
Neurogene made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2637 holding.
Mariner first reported a position in Neurogene in Q4 2024 and has held it in 3 quarters since.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.